Generic drug companies are demanding that pharmaceutical companies post a financial “bond” that they would forfeit if they lose litigation designed to prevent the loss of patents on their medicines.

In submissions to the European Commission, the European Generic Medicines Association calls for a mechanism to ringfence up to 20 per cent of the sales from any medicine on which a drug company seeks to maintain its exclusivity through legal action once the patents expire.